NCT02291913: A reported trial by SCRI Development Innovations, LLC
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02291913 |
|---|---|
| Title | Phase II Open Label Study of Everolimus in Combination With Anti-estrogen Therapy in Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Dec. 18, 2014 |
| Completion date | Jan. 31, 2019 |
| Required reporting date | Jan. 31, 2020, midnight |
| Actual reporting date | Jan. 28, 2020 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |